Commercial Lilly falls on slower start for Foundayo versus Wegovy PharmaphorumSky-high expectations for sales of Eli Lilly's new oral GLP-1 agonist Foundayo have been dented by preliminary sales data from IQVIA.Metabolic & GLP-1Read full story pharminent April 27, 2026 (Last updated: April 27, 2026) Pharmaphorum Sky-high expectations for sales of Eli Lilly’s new oral GLP-1 agonist Foundayo have been dented by preliminary sales data from IQVIA. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: UK biotech could be bound for recovery, BIA report revealsNext: New NIHR-funded TRC for Parkinson’s disease Related Stories Commercial Moderna builds commercial muscle as new launches loom pharminent June 17, 2026 Commercial ADA ’26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option pharminent June 8, 2026 Commercial Lilly and Novo face off at ADA 2026 as others seek to compete in obesity pharminent June 5, 2026
